FOGHORN THERAPEUTICS INC. - COMMON STOCK

Foghorn Therapeutics to Participate in the BMO Oncology Summit

01 أكتوبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer

03 سبتمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September

28 أغسطس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update

08 أغسطس 2024 07:00:01 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June

28 مايو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline

22 مايو 2024 18:21:05 بحسب Nasdaq GlobeNewswire

Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants

20 مايو 2024 07:58:16 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update

06 مايو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer

16 أبريل 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs

09 أبريل 2024 16:30:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference

05 أبريل 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting

26 مارس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook

07 مارس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909

05 مارس 2024 16:48:55 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference

28 فبراير 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor

08 فبراير 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024

08 يناير 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics Announces CFO Departure

03 يناير 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hematology Annual Meeting

01 ديسمبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update

02 نوفمبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire